# Auto Review: results.txt

Generated: 2026-04-28 19:46
Reviewer: Qwen2.5-32B-Instruct-AWQ (auto_review.py)

## Summary

- **Samples**: 30
- **Clean**: 0/30
- **P0** (hallucination): 0
- **P1** (major error): 28
- **P2** (minor issue): 122

### Critical Issues

- **ROW 6** [P1]: The note mentions 'lanreotide', not 'capecitabine'.
- **ROW 6** [P1]: The date mentioned is from 2015, which is not relevant to the current visit. This could be misleading.
- **ROW 7** [P1]: Inaccurate staging information. The correct staging is pT3 N1, not Stage II-III.
- **ROW 14** [P1]: Inaccurate description of the tumor location. The tumor is of duodenal/ampullary origin, not pancreatic.
- **ROW 15** [P1]: Incomplete sentence with missing critical information (specific medication name).
- **ROW 31** [P1]: This sentence contains medical jargon that may not be understood by an 8th-grade reader.
- **ROW 31** [P1]: This sentence uses medical jargon that may not be understood by an 8th-grade reader.
- **ROW 32** [P1]: Incomplete sentence, missing the name of the chemotherapy combination.
- **ROW 33** [P1]: Unexplained medical jargon 'enhancement'.
- **ROW 33** [P1]: Unexplained medical jargon 'Cancer Antigen 19-9' and 'Carcinoembryonic Antigen'.
- **ROW 33** [P1]: Incomplete sentence 'Dose reduction of irinotecan by 20% starting with cycle 2.'
- **ROW 33** [P1]: Unexplained medical jargon 'monitor your medication levels'.
- **ROW 35** [P1]: The term 'adenocarcinoma' is not explained, which could be confusing for an 8th-grade reading level.
- **ROW 35** [P1]: CA 19-9 is not explained, which could be confusing for an 8th-grade reading level.
- **ROW 35** [P1]: The term 'hereditary pancreatic cancer syndrome' is not explained, which could be confusing for an 8th-grade reading level.
- **ROW 36** [P1]: Incomplete sentence with missing critical information.
- **ROW 40** [P1]: Incomplete sentence with missing critical information (dose amount).
- **ROW 41** [P1]: This sentence contains medical jargon ('hepatic lesion', 'soft tissue') that might not be clear to an 8th-grade reader.
- **ROW 41** [P1]: This sentence is somewhat complex and uses medical jargon ('stable disease').
- **ROW 77** [P1]: The sentence is too long and complex for an 8th-grade reading level.
- **ROW 77** [P1]: The sentence contains medical jargon (AST, ALT) without explanation.
- **ROW 77** [P1]: This sentence is incomplete as there are no current medications listed.
- **ROW 79** [P1]: The term 'adenocarcinoma' is not explained, which could be confusing for an 8th-grade reading level.
- **ROW 84** [P1]: The sentence contains an error where 'consideration of a medication' should be replaced with a more appropriate term such as 'treatment'.
- **ROW 87** [P1]: Incomplete sentence, missing dosage information.
- **ROW 90** [P1]: The note mentions both primary pancreatic neuroendocrine tumor and metastatic BRAF mutant melanoma, but the extracted data only lists 'Primary pancreatic neuroendocrine tumor'.
- **ROW 90** [P1]: The note indicates the patient is on intermittent dabrafenib and trametinib for melanoma, but this is not reflected in the extracted data.
- **ROW 90** [P1]: Incomplete sentence with missing critical information.

---

## ROW 1 — ⚠️ ISSUES

**Type**: Moderately differentiated pancreatic adenocarcinoma
**Stage**: Potentially resectable with a regional LN involvement

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Missing cancer-related medication (palonosetron). | He initiated ***** on 03/06/2022, once his LFTs had sufficiently normalized post-stent, and is now s |
| P2 | Lab_Results | Missing initial CA 19-9 value (77,736). | Baseline *****-9 markedly elevated at 77,736 (in the context of obstructive jaundice) |
| P2 | Treatment_Changes | Missing mention of palonosetron. | He initiated ***** on 03/06/2022, once his LFTs had sufficiently normalized post-stent, and is now s |
| P2 | Treatment_Goals | Inaccurate goal description. Should include 'potentially curative' rather than just 'curative'. | We reviewed his most recent imaging studies which show, quite encouragingly, resolution of his aorto |
| P2 | Response_Assessment | Missing mention of the drop in CA 19-9 from 77,736 to 6,105. | Baseline *****-9 markedly elevated at 77,736 (in the context of obstructive jaundice) |

*Extraction summary*: Most fields are clean, but there are minor issues related to missing specific cancer-related medications and lab results.

### Letter: ✅ Clean

*Letter summary*: Letter is clean.

---

## ROW 4 — ⚠️ ISSUES

**Type**: Pancreatic ductal adenocarcinoma
**Stage**: Metastatic (Stage IV)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Missing cancer-related medication (gemcitabine-based regimen mentioned as a potential future treatment, but not listed under current medications). | We talked about potential side fx and risks, esp in terms of infectious complications, and adverse i |
| P2 | Treatment_Changes | Supportive medications listed include general pain medications (Fentanyl patch, Dilaudid) without specifying they are for cancer pain. | Symptom-wise, he is followed by our Cancer Center Symptom Management Service; his pain appears reaso |
| P2 | follow_up_next_visit | The next clinic visit is not specified, but the note indicates the patient will decide on further treatment and inform the team. | Mr. ***** will take some time to decide whether he wishes to pursue further salvage rx vs a purely p |

*Extraction summary*: Most fields are clean, but there are minor issues related to missing potential future cancer-related medications and unclear specification of the next clinic visit.

### Letter: ✅ Clean

*Letter summary*: Letter is clean.

---

## ROW 6 — ⚠️ ISSUES

**Type**: Primary pancreatic neuroendocrine tumor, grade 2, well-differentiated
**Stage**: Metastatic (Stage IV)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P1 | Current_Medications | The note mentions 'lanreotide', not 'capecitabine'. | continue lanreotide 120 mg/mo |
| P2 | Cancer_Diagnosis | The note specifies the tumor as grade 1 initially and grade 2 later. The extracted data only mentions grade 2. | Pathology(+) 5.5cm well-differentiated neuroendocrine tumor, grade 1 (ki-67% <2%)... *****-67: 19.7% |

*Extraction summary*: Major error in medication and minor issue in cancer grading. Other fields are clean.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | The date mentioned is from 2015, which is not relevant to the current visit. This could be misleading. | Imaging from October 5, 2015, shows that the cancer in your liver and lymph node |
| P2 | The letter does not specify the frequency or dosage of lanreotide, which might be important for the patient to know. | You continue to take lanreotide. |
| P2 | This sentence uses medical jargon that might not be clear to an 8th-grade reader. | Future treatment options include liver-directed therapy, everolimus, sunitinib,  |

*Letter summary*: The letter contains some issues that need addressing to ensure clarity and accuracy for the patient.

---

## ROW 7 — ⚠️ ISSUES

**Type**: Well-differentiated pancreatic ductal adenocarcinoma
**Stage**: pT3 N1

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Incomplete. The note mentions metformin, methylphenidate, ondansetron, and oxycodone, but only ondansetron and oxycodone are listed under supportive_meds. However, only cancer-related medications should be included in current_meds. | Medications the patient states to be taking prior to today's encounter. METFORMIN HCL (METFORMIN ORA |
| P2 | Treatment_Changes | Incomplete. The note mentions that the patient is currently receiving adjuvant chemotherapy with gemcitabine alone after discontinuing [REDACTED]-paclitaxel due to cumulative peripheral sensory neuropathy. The extraction does not mention the initial combination therapy. | He started with the combination of gemcitabine plus [REDACTED]-paclitaxel, but due to cumulative neu |
| P2 | Treatment_Goals | Inaccurate. The goal is adjuvant therapy, not curative. The note mentions that the patient is receiving adjuvant chemotherapy. | He started with the combination of gemcitabine plus [REDACTED]-paclitaxel, but due to cumulative neu |
| P2 | Response_Assessment | Inaccurate. The response assessment should include the patient's current condition and the absence of disease recurrence, not just the improvement in labs. | The patient's labs are noted to be significantly improved, allowing continuation of gemcitabine. The |
| P2 | Medication_Plan | Incomplete. The note mentions that the patient is currently receiving adjuvant chemotherapy with gemcitabine alone after discontinuing [REDACTED]-paclitaxel due to cumulative peripheral sensory neuropathy. The extraction does not mention the initial combination therapy. | He started with the combination of gemcitabine plus [REDACTED]-paclitaxel, but due to cumulative neu |
| P2 | Therapy_plan | Incomplete. The note mentions that the patient is currently receiving adjuvant chemotherapy with gemcitabine alone after discontinuing [REDACTED]-paclitaxel due to cumulative peripheral sensory neuropathy. The extraction does not mention the initial combination therapy. | He started with the combination of gemcitabine plus [REDACTED]-paclitaxel, but due to cumulative neu |

*Extraction summary*: Most fields are clean, but there are minor issues with completeness and accuracy in medication and treatment plans.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | Inaccurate staging information. The correct staging is pT3 N1, not Stage II-III. | You have a well-differentiated pancreatic ductal adenocarcinoma (cancer that sta |
| P2 | Unnecessary detail about the date of the CT scan. It can be simplified. | Recent CT scan on 10/21/2015 shows post-operative changes without evidence of re |
| P2 | Lacks context about why the treatment was changed. | You are currently receiving adjuvant chemotherapy with gemcitabine alone. |

*Letter summary*: The letter contains inaccuracies in staging information and overly detailed dates, which can be simplified for better readability.

---

## ROW 14 — ⚠️ ISSUES

**Type**: Grade 3 neuroendocrine tumor of duodenal/ampullary origin
**Stage**: Metastatic (Stage IV)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Incomplete. Missing temozolomide. | She is now s/p 5 cycles of chemotherapy consisting of the combination of capecitabine/temozolomide. |
| P2 | Treatment_Changes | Incomplete. Missing dose adjustments of capecitabine due to renal insufficiency. | Because of progressive renal insufficiency early on during her treatment course, I dose reduced her  |

*Extraction summary*: Most fields are clean, but there are minor omissions regarding current medications and treatment changes.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | Inaccurate description of the tumor location. The tumor is of duodenal/ampullary origin, not pancreatic. | You came in for a follow-up visit regarding your neuroendocrine tumor of the pan |
| P2 | Minor readability issue. Could be more explicit about what 'stable' means. | MRI scans from early June showed that your disease is stable. |
| P2 | Could be more specific about what was checked during the physical exam. | During your physical exam, no new issues were found. |
| P2 | Minor readability issue. Could specify what side effects these medications manage. | You will continue to take ondansetron and oxycodone to manage side effects. |
| P2 | Minor readability issue. Could specify the purpose of the CT scan more clearly. | After this cycle, you will have a CT scan to check on your tumor. |

*Letter summary*: The letter contains inaccuracies and minor readability issues that need addressing.

---

## ROW 15 — ⚠️ ISSUES

**Type**: Metastatic adenocarcinoma of the pancreas
**Stage**: Originally Stage IV, now metastatic (Stage IV)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Cancer_Diagnosis.Stage_of_Cancer | The note does not explicitly state the original stage of the cancer, only that it is metastatic adenocarcinoma of the pancreas. The extraction infers 'Originally Stage IV, now metastatic (Stage IV)', which is slightly imprecise. | This is a very pleasant 35-year-old Hispanic male who was diagnosed in October 2015 with metastatic  |
| P2 | Treatment_Changes.recent_changes | The note mentions that the patient will resume an unspecified agent, but the exact nature of the previous treatment is not clear. The extraction states 'He responded initially quite well to [REDACTED]', which is slightly imprecise without specifying the treatment. | We will resume [REDACTED]. He responded initially quite well to [REDACTED] but because of his residu |
| P2 | Imaging_Plan.imaging_plan | The note mentions a recent CT scan, but it does not specify future imaging plans. The extraction states 'CT Chest', which is slightly imprecise without further context. | Report dictated by: ***** ***** *****, MD, signed by: ***** ***** *****, MD Department of Radiology  |

*Extraction summary*: Most fields are clean, but there are minor issues with the inferred stage, unspecified treatment, and future imaging plan.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | Incomplete sentence with missing critical information (specific medication name). | We will resume a medication. You initially responded well to a medication, but d |

*Letter summary*: Letter has a critical issue with incomplete medication information.

---

## ROW 17 — ⚠️ ISSUES

**Type**: Adenocarcinoma of the pancreas
**Stage**: Metastatic (Stage IV)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Reason_for_Visit.summary | The summary mentions 'returning for follow-up imaging and chemotherapy management,' but the note only specifies follow-up imaging. | She has now had 4 full cycles and returns today for follow-up imaging. |
| P2 | Treatment_Changes.recent_changes | The recent changes mention starting denosumab, but it's not clear if this is a new addition or part of the ongoing treatment plan. | We plan to start denosumab. |
| P2 | Imaging_Plan.imaging_plan | The imaging plan only mentions 'CT Chest,' but the note indicates both CT abdomen/pelvis and CT chest were performed. | CT ABDOMEN/PELVIS WITH CONTRAST... CT CHEST WITH CONTRAST |

*Extraction summary*: Most fields are clean, but there are minor issues with the summary, recent treatment changes, and imaging plan.

### Letter: ✅ Clean

*Letter summary*: Letter is clean.

---

## ROW 18 — ⚠️ ISSUES

**Type**: Pancreatic ductal adenocarcinoma, grade 2, with separate intra-ampullary papilla
**Stage**: Originally Stage IB, now metastatic (Stage IV)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Missing cancer-related medications. | Medication Instructions section lists general medications only. |
| P2 | Treatment_Changes | Supportive medications listed are not fully comprehensive. | Supportive medications mentioned are ondansetron, prochlorperazine, and loperamide, but the note men |
| P2 | Treatment_Goals | Goals of treatment are labeled as 'palliative', but the note suggests a mix of palliative and possibly curative intent. | The note discusses various treatment options including clinical trials and systemic treatments, sugg |
| P2 | Response_Assessment | The response assessment is slightly imprecise. | The note states that the patient has modest interval progression in pulmonary metastases, but the ex |
| P2 | Medication_Plan | The medication plan is somewhat vague due to redactions. | The note mentions specific regimens like gemcitabine plus nab-paclitaxel, but the exact details are  |
| P2 | Therapy_plan | The therapy plan is somewhat vague due to redactions. | The note mentions specific regimens like gemcitabine plus nab-paclitaxel, but the exact details are  |
| P2 | Procedure_Plan | The procedure plan is somewhat vague due to redactions. | The note mentions referring to Rad Onc team for assessment of candidacy for radiotherapy, but the ex |

*Extraction summary*: Most fields are clean, but there are minor issues with missing cancer-related medications, incomplete supportive medications, and slightly imprecise treatment plans due to redactions.

### Letter: ✅ Clean

*Letter summary*: Letter is clean.

---

## ROW 21 — ⚠️ ISSUES

**Type**: Metastatic pancreatic cancer
**Stage**: Metastatic (Stage IV)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Missing cancer-related medication (irinotecan). | On this basis, he initiated 2nd-line chemotherapy consisting of the combination of 5-*****/LV plus * |
| P2 | Treatment_Changes | Missing detail about dose reduction of irinotecan. | Due to obstipation and anorexia following cycle #1, his doses were reduced by 20% beginning with cyc |
| P2 | Therapy_plan | Incorrectly states 'Continue/start: irinotecan'. The patient is no longer a candidate for further treatment. | Therefore we had a ***** goals of care discussion in which I recommended that he refocus his goals p |

*Extraction summary*: Most fields are clean, but there are minor issues regarding the inclusion of cancer-related medications and the therapy plan.

### Letter: ✅ Clean

*Letter summary*: Letter is clean.

---

## ROW 29 — ⚠️ ISSUES

**Type**: Metastatic adenocarcinoma of the pancreas
**Stage**: 

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Reason_for_Visit.summary | Inaccurate summary; mentions 'new diagnosis' instead of 'follow-up'. | This is an independent visit. |
| P2 | Cancer_Diagnosis.Stage_of_Cancer | Stage not specified, though it can be inferred as Stage IV due to metastasis. | Metastatic adenocarcinoma of the pancreas |
| P2 | Current_Medications.current_meds | Incomplete; only lists Gemcitabine and Abraxane, missing other cancer-related medications like Zoledronic acid. | Gemcitabine 1000 mg/m2 fixed dose rate on days 1 & 15, Abraxane 125 mg/m2 on days 1 & 15 |
| P2 | Treatment_Changes.recent_changes | Incomplete; only lists Gemcitabine and Abraxane, missing other cancer-related medications like Zoledronic acid. | Restarted Gemcitabine + Abraxane |
| P2 | Medication_Plan.medication_plan | Incomplete; only lists Gemcitabine and Abraxane, missing other cancer-related medications like Zoledronic acid. | Gemcitabine 1000 mg/m2 fixed dose rate on days 1 & 15, Abraxane 125 mg/m2 on days 1 & 15, Lasix 20 m |
| P2 | Therapy_plan.therapy_plan | Incomplete; only lists Gemcitabine and Abraxane, missing other cancer-related medications like Zoledronic acid. | Gemcitabine 1000 mg/m2 fixed dose rate on days 1 & 15 and Abraxane 125 mg/m2 on days 1 & 15. Will pr |

*Extraction summary*: Most fields are clean, but there are minor issues with the summary, stage specification, and completeness of cancer-related medications.

### Letter: ✅ Clean

*Letter summary*: Letter is clean.

---

## ROW 31 — ⚠️ ISSUES

**Type**: Metastatic adenocarcinoma of the pancreas
**Stage**: 

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Cancer_Diagnosis.Stage_of_Cancer | Stage of cancer is missing, though it could be inferred as Stage IV due to metastasis. | Metastatic adenocarcinoma the pancreas improving on therapy with resolution of ascites |
| P2 | Current_Medications.current_meds | Missing specific details about the dosage and schedule of gemcitabine. | He is now been through 3 cycles of alternate week fixed dose rate gemcitabine. |
| P2 | Treatment_Changes.recent_changes | Field is empty, but there might be relevant changes in supportive care or other treatments not captured. | He continues on treatment without schedule or dose modification. |

*Extraction summary*: Most fields are clean, but there are minor issues related to missing stage information, incomplete medication details, and potential omissions in treatment changes.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | This sentence contains medical jargon that may not be understood by an 8th-grade reader. | Your white blood cell count is high, and your red blood cell count, hemoglobin,  |
| P1 | This sentence uses medical jargon that may not be understood by an 8th-grade reader. | Additionally, your Cancer Antigen 19-9 level is elevated. |

*Letter summary*: The letter contains some medical jargon that may not be easily understood by an 8th-grade reader.

---

## ROW 32 — ⚠️ ISSUES

**Type**: Metastatic moderately differentiated adenocarcinoma of pancreatic or biliary ori
**Stage**: Stage IV (metastatic to liver, lungs, skeleton, peritoneum)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Missing cancer-related medication (gemcitabine) mentioned in the note. | There are several possible chemotherapy options for metastatic pancreatic cancer, with the choice of |
| P2 | Treatment_Changes | Supportive medications listed are not exclusively cancer-treatment-related. | Supportive medications include primary prophylaxis with growth factor support ([REDACTED] or Neupoge |
| P2 | Treatment_Goals | Goals of treatment should be more specific (e.g., palliative with disease control and symptom management). | The goals of such treatment are to produce disease control and hopefully extend survival, while poss |
| P2 | Medication_Plan | Missing specific cancer-related medication (gemcitabine) mentioned in the note. | The patient is inclined to move ahead with standard of care (SOC) chemotherapy with [REDACTED]. |
| P2 | Therapy_plan | Specific cancer-related therapy (gemcitabine) is not mentioned. | The patient is inclined to move ahead with standard of care (SOC) chemotherapy with FOLFIRINOX. |

*Extraction summary*: Most fields are clean, but there are minor issues related to missing specific cancer-related medications and treatments.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | Incomplete sentence, missing the name of the chemotherapy combination. | You are starting standard of care (SOC) chemotherapy with a chemotherapy combina |

*Letter summary*: Letter has one incomplete sentence that needs clarification.

---

## ROW 33 — ⚠️ ISSUES

**Type**: Metastatic pancreatic adenocarcinoma with biopsy-proven liver metastasis
**Stage**: Stage IV (metastatic to liver)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Missing current cancer-related medication (irinotecan). | She was started on ***** 06/07/19 and has been tolerating it well with dose reduction of irinotecan  |
| P2 | Treatment_Changes | Inconsistent mention of irinotecan. It states 'Switch to gemcitabine combined with nab-paclitaxel' without explicitly mentioning discontinuation of irinotecan. | my recommendation is to switch her therapy to gemcitabine combined with *****-paclitaxel. |
| P2 | Treatment_Goals | The goal 'palliative' is correct but could be more specific given the context of ongoing management and switching treatments. | She has been tolerating it well with dose reduction of irinotecan by 20% starting with cycle 2. |
| P2 | Response_Assessment | The response assessment mentions 'stable disease in the liver but progressive disease in the pancreatic primary.' This is correct but could be more detailed regarding the exact nature of the progression. | The cancer is showing stable disease in the liver but progressive disease in the pancreatic primary. |
| P2 | Medication_Plan | The plan mentions 'gemcitabine 1000 mg/m2 + [REDACTED]-paclitaxel 125 mg/m2,' but does not specify the continuation or discontinuation of irinotecan. | Plan for gemcitabine 1000 mg/m2 + [REDACTED]-paclitaxel 125 mg/m2 on days 1, 8, 15 out of 28-day cyc |
| P2 | Therapy_plan | The plan mentions continuing irinotecan, but the note indicates a switch to a different regimen. | my recommendation is to switch her therapy to gemcitabine combined with *****-paclitaxel. |
| P2 | follow_up_next_visit | The next visit is mentioned as '2 weeks when she is due for [REDACTED],' but the specific test or procedure is not specified. | Next clinic visit: in-person: 2 weeks when she is due for [REDACTED] |

*Extraction summary*: Most fields are clean, but there are minor issues with the completeness and specificity of the medication and therapy plans, and the follow-up visit details.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | Unexplained medical jargon 'enhancement'. | Additionally, the radiologist noted increased enhancement around the tumor, sugg |
| P1 | Unexplained medical jargon 'Cancer Antigen 19-9' and 'Carcinoembryonic Antigen'. | Your Cancer Antigen 19-9 and Carcinoembryonic Antigen levels remain high. |
| P1 | Incomplete sentence 'Dose reduction of irinotecan by 20% starting with cycle 2.' | You switched to gemcitabine combined with nab-paclitaxel. Dose reduction of irin |
| P1 | Unexplained medical jargon 'monitor your medication levels'. | We will monitor your medication levels monthly. |

*Letter summary*: The letter contains several instances of unexplained medical jargon and an incomplete sentence that need addressing.

---

## ROW 35 — ⚠️ ISSUES

**Type**: Adenocarcinoma of pancreatic tail
**Stage**: Metastatic (Stage IV)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | The field is empty, but the note mentions that the patient is on several medications, though none are cancer-related. | Current Outpatient Prescriptions: ERGOCALCIFEROL, VITAMIN D2, escitalopram oxalate, lisinopril, lora |
| P2 | Treatment_Changes | The field is empty, but the note discusses potential future treatment changes based on the results of the biopsy and lab tests. | My recommendation would be consideration of the ***** trial to determine if the patient has high ser |

*Extraction summary*: Most fields are clean, but there are minor issues with missing non-cancer medications and potential future treatment changes.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | The term 'adenocarcinoma' is not explained, which could be confusing for an 8th-grade reading level. | You have pancreatic adenocarcinoma (cancer that started in gland cells) with fou |
| P1 | CA 19-9 is not explained, which could be confusing for an 8th-grade reading level. | You will be monitored with monthly CA 19-9 levels and restaging CT scans every 2 |
| P1 | The term 'hereditary pancreatic cancer syndrome' is not explained, which could be confusing for an 8th-grade reading level. | We will request assistance from our genetic counselors for evaluation of a possi |

*Letter summary*: The letter contains several instances where medical terms are not fully explained, which could confuse a patient reading at an 8th-grade level.

---

## ROW 36 — ⚠️ ISSUES

**Type**: Nonfunctioning pancreatic neuroendocrine tumor
**Stage**: Metastatic (Stage IV)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Incomplete. Everolimus is listed, but the note mentions multiple doses (2.5 mg and 10 mg). | everolimus (AFINITOR) 2.5 mg TAB 7.5 mg (3 tabs) daily  90 tablet  6    everolimus 10 mg TAB Take 1 |
| P2 | Treatment_Changes | Incomplete. The note mentions holding everolimus during partial SBO, but this detail is not fully captured. | Everolimus held during that period of time, resumed two weeks ago. |
| P2 | Treatment_Goals | Slightly imprecise. 'Palliative' is correct, but 'durable disease control' is also mentioned in the note. | with evidence of good durable disease control and reasonably good (in fact, improved) tolerance on c |
| P2 | Medication_Plan | Slightly imprecise. The note mentions starting non-insulin pharmacologic treatment in the future, but this is not clearly stated. | discussed potential plan to start non-insulin pharmacologic rx in the future. |

*Extraction summary*: Most fields are clean, but there are minor issues related to completeness and precision in medication details and treatment goals.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | Incomplete sentence with missing critical information. | Some liver tumors have grown slightly, while others have shrunk. |

*Letter summary*: Letter contains an incomplete sentence that needs clarification.

---

## ROW 40 — ⚠️ ISSUES

**Type**: Metastatic adenocarcinoma of the pancreas
**Stage**: 

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Missing cancer-related medications (gemcitabine and Abraxane) in the medication plan. | We recommend a course of treatment with gemcitabine and Abraxane. |

*Extraction summary*: One minor issue identified regarding the inclusion of cancer-related medications in the medication plan.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | Incomplete sentence with missing critical information (dose amount). | We plan to increase the dose of your fentanyl and added Reglan and when necessar |

*Letter summary*: Letter contains an incomplete sentence with missing critical information.

---

## ROW 41 — ⚠️ ISSUES

**Type**: Invasive adenocarcinoma, well- to moderately differentiated, with perineural inv
**Stage**: Not available (redacted), now with local recurrence

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Missing cancer-related medication information. | He is continuing with an insulin regimen and regular use of enzyme supplements with meals. |
| P2 | Treatment_Changes | Missing information about recent treatment changes. | The patient received 12 cycles of neoadjuvant chemotherapy with essentially stable disease. |
| P2 | Imaging_Plan | Missing recommendation for PET/CT. | Further evaluation with PET/CT may be helpful for confirmation. |

*Extraction summary*: Most fields are clean, but there are minor issues related to missing cancer-related medication information, recent treatment changes, and imaging recommendations.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | This sentence contains medical jargon ('hepatic lesion', 'soft tissue') that might not be clear to an 8th-grade reader. | A hepatic lesion in your liver has decreased in size, while there is an increase |
| P1 | This sentence is somewhat complex and uses medical jargon ('stable disease'). | The treatment you received before surgery resulted in stable disease in the live |

*Letter summary*: The letter contains minor readability issues that could confuse an 8th-grade reader.

---

## ROW 43 — ⚠️ ISSUES

**Type**: Pancreatic adenocarcinoma
**Stage**: Borderline resectable pancreatic adenocarcinoma due to <180 degrees of vascular 

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Missing cancer-related medications. | The note mentions 'Continue to monitor [REDACTED] July 04 [REDACTED] 4 weeks.' and 'Continue [REDACT |

*Extraction summary*: Most fields are clean, but the current medications related to cancer treatment are missing.

### Letter: ✅ Clean

*Letter summary*: Letter is clean.

---

## ROW 59 — ⚠️ ISSUES

**Type**: Well to moderately differentiated adenocarcinoma of the pancreas with pulmonary 
**Stage**: Originally unspecified, now with pulmonary recurrence (Stage IV)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Cancer_Diagnosis.Stage_of_Cancer | The stage is described as 'Originally unspecified, now with pulmonary recurrence (Stage IV)', which may be misleading given the current status of no evidence of disease. | Adenocarcinoma of the pancreas, status post resection in 2012 followed by adjuvant therapy with pulm |
| P2 | Current_Medications.current_meds | The field is empty, but the note mentions methimazole for hyperthyroidism, which is related to the patient's cancer history. | She was found to be hyperthyroid and she is now being treated with methimazole. |
| P2 | Treatment_Changes.recent_changes | The field is empty, but the note indicates ongoing surveillance and no recent changes. | She will continue on surveillance. We'll see her again in 6 months. |
| P2 | Imaging_Plan.imaging_plan | The field only mentions 'CT Chest', but the note specifies both 'CT Chest' and 'CT Abdomen/Pelvis'. | Compared to 01/04/2022, no evidence of recurrent or metastatic disease within the abdomen and pelvis |

*Extraction summary*: Most fields are clean, but there are minor issues with the staging description, current medications, recent treatment changes, and imaging plan.

### Letter: ✅ Clean

*Letter summary*: Letter is clean.

---

## ROW 62 — ⚠️ ISSUES

**Type**: Pancreatic ductal adenocarcinoma
**Stage**: Originally Stage IIB, now metastatic (Stage IV)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Cancer_Diagnosis.Stage_of_Cancer | The note does not specify the original stage of the cancer, only that it is now metastatic. | The note mentions 'resected pancreaticobiliary cancer' and 'recurred with metastatic disease to the  |
| P2 | Treatment_Changes.recent_changes | The note specifies the start date of the treatment but does not mention the exact drug name. | Started [REDACTED] [REDACTED] 11/05/20 |
| P2 | Genetic_Testing_Plan.genetic_testing_plan | The note mentions asking medical genetics to weigh in on the mutation but does not provide specific details. | I will ask medical genetics to weigh in on the [REDACTED] of the ATM [REDACTED] mutation and overlay |

*Extraction summary*: Most fields are clean, but there are minor issues with the staging, recent treatment changes, and genetic testing plan.

### Letter: ✅ Clean

*Letter summary*: Letter is clean.

---

## ROW 72 — ⚠️ ISSUES

**Type**: Moderately differentiated adenocarcinoma
**Stage**: Originally borderline resectable, now metastatic (Stage IV)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Cancer_Diagnosis.Stage_of_Cancer | The stage 'Originally borderline resectable, now metastatic (Stage IV)' is slightly imprecise. The note mentions the initial stage as borderline resectable but does not explicitly state the current stage as Stage IV. | He presented in December 2014. CT scan, performed at ***** for abdominal and back pain, demonstrated |
| P2 | Treatment_Changes.recent_changes | The recent changes mention switching to reduced dose [REDACTED], but the exact name of the medication is redacted. This could be clearer. | We elected to resume chemotherapy but switched to reduced dose [REDACTED]. After 8 cycles, he had st |

*Extraction summary*: Most fields are clean, but there are minor issues with the staging and recent treatment changes.

### Letter: ✅ Clean

*Letter summary*: Letter is clean.

---

## ROW 77 — ⚠️ ISSUES

**Type**: Adenocarcinoma of the tail of the pancreas
**Stage**: Resectable at diagnosis, now on surveillance

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Reason_for_Visit.summary | The summary mentions 'follow-up visit for adjuvant therapy with gemcitabine and capecitabine', but the note states that he has already completed 6 cycles of adjuvant therapy. | He has had 6 cycles and is on surveillance. |
| P2 | Cancer_Diagnosis.Stage_of_Cancer | The stage is described as 'Resectable at diagnosis, now on surveillance'. While accurate, it could be more precise by specifying the current status as 'NED' (no evidence of disease). | Within this limitation, no evidence of recurrent or metastatic disease in abdomen or pelvis. |
| P2 | Treatment_Changes.recent_changes | The field is empty, but the note indicates that the patient has completed adjuvant therapy and is now on surveillance. This should be reflected. | He has had 6 cycles and is on surveillance. |
| P2 | Response_Assessment.response_assessment | The field states 'Not yet on treatment — no response to assess.' However, the patient has completed adjuvant therapy and is now on surveillance. | He has had 6 cycles and is on surveillance. |
| P2 | Imaging_Plan.imaging_plan | The imaging plan only mentions 'CT Abdomen', but the note suggests a comprehensive surveillance plan which may include both abdomen and chest imaging. | CT Abdomen /Pelvis without Contrast... CT Chest without contrast |

*Extraction summary*: Most fields are clean, but there are minor issues regarding the completion of adjuvant therapy and the specificity of the imaging plan.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | The sentence is too long and complex for an 8th-grade reading level. | You have adenocarcinoma (cancer that started in gland cells) of the tail of the  |
| P1 | The sentence contains medical jargon (AST, ALT) without explanation. | However, your liver function tests show elevated levels of AST (162 U/L) and ALT |
| P1 | This sentence is incomplete as there are no current medications listed. | No changes were made to your current medications or treatments. |

*Letter summary*: The letter contains issues with readability and completeness that need addressing.

---

## ROW 79 — ⚠️ ISSUES

**Type**: Pancreatic adenocarcinoma with metastatic disease to liver
**Stage**: Metastatic (Stage IV)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | The field is empty, but the note mentions no cancer-related medications. | Medications the patient states to be taking prior to today's encounter. |
| P2 | Treatment_Goals | The field states 'palliative', but the note suggests a goal of achieving a deep and durable remission, which aligns more closely with 'curative intent'. | the mainstay of treatment at this juncture should consist of systemic therapy with the goal of achie |
| P2 | follow_up_next_visit | The field states 'No explicit timing or mention of next clinic visit in the document.' However, the note implies a follow-up within the next week for starting treatment. | starting treatment in the next week or so |

*Extraction summary*: Most fields are clean, but there are minor issues with the classification of treatment goals, the completeness of current medications, and the clarity of follow-up timing.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | The term 'adenocarcinoma' is not explained, which could be confusing for an 8th-grade reading level. | You have been diagnosed with pancreatic adenocarcinoma (cancer that started in g |
| P2 | While 'CA 19-9' is mentioned, it is not fully explained in simple terms. | Tests show that your CA 19-9 (a tumor marker) level is high at 852. |
| P2 | The term 'complex cystic and solid mass' is somewhat technical and could be simplified. | Imaging and biopsy confirm a complex cystic and solid mass in the tail of your p |

*Letter summary*: The letter contains minor issues with medical jargon that could confuse an 8th-grade reader. Some terms need further simplification.

---

## ROW 82 — ⚠️ ISSUES

**Type**: Pancreatic adenocarcinoma
**Stage**: Stage IV (metastatic to liver and lung)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Missing current cancer-related medication (fentanyl patch). | fentaNYL (DURAGESIC) 25 mcg/hr patch Place 1 patch onto the skin every other day. For cancer pain. |

*Extraction summary*: One minor issue found in Current_Medications.

### Letter: ✅ Clean

*Letter summary*: Letter is clean.

---

## ROW 84 — ⚠️ ISSUES

**Type**: Pancreatic adenocarcinoma
**Stage**: Originally Stage III, now metastatic (Stage IV)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Incomplete. Current medications should include both atezolizumab and cobimetinib. | Now midway through cycle #2 of treatment on the crossover arm of the same [REDACTED] trial consistin |
| P2 | Treatment_Changes | Incomplete. Should mention both atezolizumab and cobimetinib. | Switched to the combination of atezolizumab, a PD-L1 inhibitor (administered on a q2 weekly schedule |
| P2 | Treatment_Goals | Inaccurate. Given the context, 'palliative' is too broad; 'symptom management' might be more precise. | He is tolerating treatment very well with no ***** or MEK-related toxicities, and maintenance of a g |
| P2 | Genetic_Testing_Plan | Inaccurate. 'pd-l1' is not mentioned in the note. | No specific genetic testing plans mentioned. |

*Extraction summary*: Most fields are clean, but there are minor issues with completeness and accuracy in medication and genetic testing plans.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | The sentence contains an error where 'consideration of a medication' should be replaced with a more appropriate term such as 'treatment'. | At the point you progress on this regimen, you could see a radiation oncologist  |

*Letter summary*: Letter has one minor factual error that needs correction.

---

## ROW 87 — ⚠️ ISSUES

**Type**: Well-differentiated pancreatic neuroendocrine tumor (PNET) with metastatic disea
**Stage**: Metastatic (Stage IV)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Missing octreotide, which is a cancer-related medication. | octreotide (SANDOSTATIN *****) 30 mg every 30 (thirty) days. |
| P2 | Treatment_Changes | Missing mention of increased metformin dosage. | Recent metformin and exercise for higher sugars- now fine. |
| P2 | Treatment_Goals | Should be 'palliative' but could be more specific given the context. | Tolerating Everolimus well--continue with Everolimus 10 mg daily |
| P2 | Response_Assessment | Could be more precise about the nature of the progression. | My interpretation is that there is slow PD v December 2016 |
| P2 | Medication_Plan | Missing mention of increased metformin dosage. | Recent metformin and exercise for higher sugars- now fine. |
| P2 | Procedure_Plan | Mentions liver directed therapy but does not specify it as a future plan. |  |
| P2 | Imaging_Plan | Does not mention the need for a follow-up H&P and chest CT. | Needs f/u H&P and chest CT 3 mo-- sooner if sx |
| P2 | Lab_Plan | Does not mention the need to follow up MMA and B12. | On oral replacement- -needs f/u MMA, and B12 |

*Extraction summary*: Most fields are clean, but there are minor issues regarding completeness and specificity in several fields.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | Incomplete sentence, missing dosage information. | You will continue taking Everolimus . |
| P2 | Unexplained medical term 'bruises'. | You have multiple small bruises noted on physical exam. |
| P2 | Unexplained medical term 'triglycerides'. | You are also advised to continue monitoring your triglycerides quarterly. |

*Letter summary*: The letter has minor issues with incomplete sentences and unexplained medical terms.

---

## ROW 90 — ⚠️ ISSUES

**Type**: Primary pancreatic neuroendocrine tumor
**Stage**: 

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P1 | Cancer_Diagnosis.Type_of_Cancer | The note mentions both primary pancreatic neuroendocrine tumor and metastatic BRAF mutant melanoma, but the extracted data only lists 'Primary pancreatic neuroendocrine tumor'. | Regarding her metastatic ***** mutant melanoma (started on heel, 3 LNs in knee and 5 LNs in groin -> |
| P1 | Current_Medications.current_meds | The note indicates the patient is on intermittent dabrafenib and trametinib for melanoma, but this is not reflected in the extracted data. | continues on clinical trial, taking intermittent dabrafenib +***** ***** then trametinib alone ***** |
| P2 | Treatment_Changes.recent_changes | The note suggests reducing the dose of octreotide, but the extracted data does not clearly indicate the reason for the change. | Given documented ***** to liver-- favor trial of somatostatic analog (based on clarinet data showing |
| P2 | Treatment_Goals.goals_of_treatment | The note implies a mixed goal of managing both the pNET and melanoma, but the extracted data only states 'palliative'. | I'd like to avoid sunitinib or everolimus or chemotherapy given need for ongoing ***** inhibitor. |

*Extraction summary*: Major errors include missing metastatic BRAF mutant melanoma and current melanoma treatments. Minor issues involve unclear reasons for medication changes and incomplete treatment goals.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | Incomplete sentence with missing critical information. | Your dose of octreotide was reduced to for four days, then increased to for anot |

*Letter summary*: Letter contains an incomplete sentence with missing critical information.

---

## ROW 91 — ⚠️ ISSUES

**Type**: Adenocarcinoma of the pancreas, moderately differentiated
**Stage**: Originally Stage III, now with residual adenocarcinoma and 8 of 23 lymph nodes p

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Cancer_Diagnosis.Stage_of_Cancer | The note does not specify the original stage of the cancer, only mentions 'early stage pancreatic adenocarcinoma'. The extracted 'Originally Stage III' is an assumption. | Mr. ***** is a 55 y/o man with a h/o HTN and a recent diagnosis of early stage pancreatic adenocarci |
| P2 | Treatment_Changes.recent_changes | The note mentions the patient has completed 6 cycles of therapy with gemcitabine and Abraxane, but the extracted data does not reflect any recent changes in treatment. | He has completed 6 cycles of therapy. His last 2 cycles were given with alternate week schedule usin |
| P2 | Treatment_Changes.supportive_meds | The note does not mention any specific supportive medications used during the treatment, but the absence of supportive medications might be worth noting. | None |
| P2 | Treatment_Goals.goals_of_treatment | The note suggests the patient has completed neoadjuvant therapy and surgery, and is now under surveillance. The goal 'curative' might be misleading without specifying the context of surveillance. | Currently, the patient is asymptomatic with stable disease. |
| P2 | Response_Assessment.response_assessment | The note mentions possible local recurrence, but the extracted response assessment does not reflect this possibility explicitly. | He may well have local recurrence but with the current coronavirus crisis, it will be difficult to w |

*Extraction summary*: Most fields are clean, but there are minor issues regarding the assumed original stage, lack of recent treatment changes, and the clarity of treatment goals and response assessment.

### Letter: ✅ Clean

*Letter summary*: Letter is clean.

---

## ROW 92 — ⚠️ ISSUES

**Type**: Moderately differentiated pancreatic ductal adenocarcinoma with perineural and l
**Stage**: Originally borderline resectable, now metastatic (Stage IV)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Cancer_Diagnosis.Type_of_Cancer | The note does not specify 'perineural and lymphovascular invasion' in the initial diagnosis. | Ms. ***** is a 63 y.o. female whom I am seeing at the UCSF Comprehensive Cancer Center for follow-up |
| P2 | Cancer_Diagnosis.Stage_of_Cancer | The note mentions 'borderline resectable' initially, but the current status is 'metastatic (Stage IV)', which might be misleading. | This pleasant woman was originally diagnosed with borderline resectable disease back in November 201 |
| P2 | Lab_Results.lab_summary | The note does not provide specific lab values mentioned in the extracted data. | Her *****-9 levels gradually ***** upwards, with a CT scan performed here at ***** on 12/10/2018 sho |
| P2 | Current_Medications.current_meds | The note does not mention any current cancer-related medications, but the extracted data should reflect the ongoing treatment with gemcitabine and [REDACTED]-paclitaxel. | She has since opted to resume chemotherapy with gemcitabine/*****-paclitaxel, well-tolerated to date |
| P2 | Treatment_Changes.recent_changes | The note does not mention any recent changes in treatment, but the extracted data should reflect the ongoing treatment with gemcitabine and [REDACTED]-paclitaxel. | She has since opted to resume chemotherapy with gemcitabine/*****-paclitaxel, well-tolerated to date |

*Extraction summary*: Most fields are clean, but there are minor issues with the cancer diagnosis details, lab results, and current medications.

### Letter: ✅ Clean

*Letter summary*: Letter is clean.

---

## ROW 98 — ⚠️ ISSUES

**Type**: Metastatic adenocarcinoma of the pancreas
**Stage**: Metastatic (Stage IV)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Missing cancer-related medication (gemcitabine and Abraxane). | We initially saw her about 2 months ago. We recommended therapy with gemcitabine and Abraxane. |
| P2 | Treatment_Changes | Supportive medications listed are incomplete. Missing LORazepam (ATIVAN) and predniSONE (DELTASONE). | LORazepam (ATIVAN) 1 mg tablet... predniSONE (DELTASONE) 20 mg tablet... |
| P2 | Lab_Plan | Incorrect classification. Should be under 'Therapy_plan'. | Once we can get her albumin up to 2 or better, we can resume her chemotherapy. |

*Extraction summary*: Most fields are clean, but there are minor issues with missing cancer-related medications and misclassified lab plan.

### Letter: ✅ Clean

*Letter summary*: Letter is clean.

---

